Researchers in the Netherlands based at the Leiden University Medical Center (LUMC) announced they are preparing to launch a “human challenge trial,” in which willing volunteers would be deliberately exposed to the SARS-CoV-2 coronavirus under controlled conditions to test vaccines and study the disease. 
These researchers have not yet decided to conduct the trial, which would still need regulatory approval to begin, stated a press release issued on November 25, 2020.

The Advisory Committee on Immunization Practices (ACIP) held an out-of-schedule, emergency meeting to discuss various issues related to experimental COVID-19 vaccine candidates.
Held at the US Centers for Disease Control and Prevention (CDC)’s Atlanta, Georgia Healthquarters, this digital meeting was opened by the Director Dr. Robert R. Redfield on November 23, 2020. 

The University of Oxford and its vaccine production partner AstraZeneca announced positive high-level results from an initial analysis of clinical trials of the experimental vaccine candidate, AZD1222.

The World Health Organization’s (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for the type 2 novel oral polio vaccine (nOPV2). 
This announcement on November 13, 2020, will enable the rollout of the nOPV2 vaccine for use in countries affected by circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks.
The WHO stated: ‘clinical trials of the new vaccine have shown it to be safe and provide comparable protection against polio, as the currently used type 2 monovalent OPV (mOPV2) vaccine. 

A new study published in the journal of the American Society for Microbiology indicates that the mumps IgG titers, or levels of IgG antibody, are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with the measles-mumps-rubella (MMR) vaccine.
Published on November 20, 2020, the researchers in this study found a significant inverse correlation (rs = -0.71, P < 0.001) between mumps titers and COVID-19 severity within the MMR II sub-group.

While Emergency Use Authorizations (EUA) have received increased attention during the COVID-19 public health emergency, they are not a new tool to the US Food and Drug Administration (FDA). 
The Commissioner of FDA Stephen M. Hahn M.D., took a moment on November 17, 2020, to reaffirm FDA’s commitment to transparency around the EUA process and share some updates on our plan to provide more information about FDA’s decisions to issue, revise or revoke EUAs for vaccines.

The World Health Organization (WHO) Global Strategy to Accelerate the Elimination of Cervical Cancer announced today marks the first time that 194 countries commit to eliminating cancer – following the adoption of a resolution at the World Health Assembly in 2020.
Cervical cancer is a preventable disease that is also curable if detected early and adequately treated. Yet it is the 4th most common cancer among women globally. 
This WHO cervical cancer strategy outlines three key steps: vaccination, screening, and treatment.

A Hyderabad-based vaccine and pharmaceutical company announced the initiation of a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India.
This early-stage study’s results are expected to be available by February 2021.

A Denmark-based vaccine producer announced that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include indications for monkeypox and related orthopoxvirus infections and disease in adults 18 years of age and older determined to be at high risk for exposure.
IMVAMUNE is currently approved in Canada under the Extraordinary Use New Drugs Pathway. 

The winter flu season may soon bring out dishonest sellers marketing fraudulent products to unsuspecting consumers, who are already concerned about protecting themselves from COVID-19, said the U.S Food and Drug Administration (FDA).
These products can be found online, including popular marketplaces, and in retail stores. They may be labeled as dietary supplements, foods, hand sanitizers, nasal sprays, or devices.